Clinical Trial Update: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study [Phase 2]

View source ↗

Summary

Phase 2a trial of SUVN-502 combined with donepezil and memantine for moderate Alzheimer's disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SUVN-502

Snippet

Sponsor: Suven Life Sciences Limited | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-06-09